Istvan Bodrogi

Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial.

William Berry, Oliver Sartor, J Alfred Witjes, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial

Bohuslav Melichar, A. Ravaud, B. Melichar, 2007, The Lancet.

Association of Genomic Domains in BRCA1 and BRCA2 with Prostate Cancer Risk and Aggressiveness.

Stefania Tommasi, Laura Cortesi, Mads Thomassen, 2019, Cancer research.